

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC

06 FEB 14 PM 4:18

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name  Ryan Phillips Utrecht & MacKinnon			
2. Address <input type="checkbox"/> Check if different than previously reported  1133 Connecticut Avenue, NW Suite 300 Washington DC 20036 USA			
3. Principal place of business (if different than line 2)  City State/Zip or Country			
4a. Contact Name Mr. Rodney C. Hoppe	b. Telephone number 202-293-1177	c. E-mail rodney@rpum.com	5. Senate ID # 30187-636
7. Client Name <input type="checkbox"/> Self Pfizer Inc.			6. House ID # 30680039

**TYPE OF REPORT** 8. Year 2005 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_ 11. No Lobbying Activity

**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>60,000</u></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) of Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>
---	--

Edit Form >

Signature Rodney C. Hoppe Date 2/14/06

Printed Name and Title Rodney C. Hoppe, Partner

0000062908



Registrant Name Ryan Phillips Utrecht & MacKinnon

Client Name Pfizer Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

H.R. 563, Prescription Drug Affordability Act of 2005  
H.R. 753/S. 184, Safe IMPORT Act of 2005, provisions dealing with pharmaceuticals  
H.R. 5/S. 1355, Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2005  
S. 455, Medicare Prescription Drug Price Reduction Act of 2005  
H. 376, Medicare's Equitable Drugs for Seniors Act of 2005  
H.R. 1626, Medicare Prescription Drug Improvement Act

17. House(s) of Congress and Federal agencies contacted  Check if None

US House  
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Berzok	
Rodney Hoppe	
Jeffrey M. MacKinnon	
Douglas R. Nappi	
George C. O'Connor	
William D. Phillips	
Mark Planning	
Thomas M. Ryan	
Joseph V. Vasapoli	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Rodney C. Hoppe, Partner

1000062908



Registrant Name Ryan Phillips Utrecht & MacKinnon

Client Name Pfizer Inc.

**ADDENDUM for General Lobbying Issue Area MMM**

16. Specific lobbying issues (continued from previous page)

S. 239, Medicare Enhancements for Needed Drugs Act of 2005  
H.R. 752/ S. 873, Medicare Prescription Drug Savings and Choice Act of 2005

0000062910



Registrant Name Ryan Phillips Utrecht & MacKinnon

Client Name Pfizer Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide the information as requested. Attach additional page(s) as needed.

15. General issue area code PHA - Pharmacy (one per page)

16. Specific lobbying issues

Legislation on issues pertaining to proposed Medical Prescription drug benefits  
Legislation on issues regarding FDA regulation of prescription drugs  
Congressional oversight of drug safety  
S. 109/H.R. 328 - Pharmaceutical Market Access Act of 2005  
H.R. 700/S. 334 - Pharmaceutical Market Access & Drug Safety Act of 2005

17. House(s) of Congress and Federal agencies contacted  Check if None

US House  
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Berzok	
Rodney Hoppe	
Jeffrey M. MacKinnon	
Douglas R. Nappi	
George C. O'Connor	
William D. Phillips	
Mark Planning	
Thomas M. Ryan	
Joseph V. Vasapoli	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

0000062911

